Financial reports
10-Q
2024 Q1
Quarterly report
24 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
10-K
2023 FY
Annual report
7 Feb 24
10-Q
2023 Q3
Quarterly report
25 Oct 23
10-Q
2023 Q2
Quarterly report
26 Jul 23
ARS
2022 FY
Annual report to shareholders
1 May 23
10-Q
2023 Q1
Quarterly report
26 Apr 23
10-K
2022 FY
Annual report
9 Feb 23
10-Q
2022 Q3
Quarterly report
26 Oct 22
10-Q
2022 Q2
Quarterly report
27 Jul 22
Current reports
8-K
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
24 Apr 24
8-K
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
26 Mar 24
8-K
Other Events
4 Mar 24
8-K
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
1 Mar 24
8-K
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
27 Feb 24
8-K
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
7 Feb 24
8-K
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
25 Oct 23
8-K
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
26 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
11 May 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
27 Feb 24
S-8
Registration of securities for employees
7 Feb 24
S-3ASR
Automatic shelf registration
26 Jul 23
424B5
Prospectus supplement for primary offering
31 Mar 23
424B5
Prospectus supplement for primary offering
29 Mar 23
S-8
Registration of securities for employees
9 Feb 23
S-8
Registration of securities for employees
9 Feb 22
424B5
Prospectus supplement for primary offering
11 Aug 21
S-3
Shelf registration
28 Jul 21
Proxies
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
PRE 14A
Preliminary proxy
17 Apr 23
DEFA14A
Additional proxy soliciting materials
7 Apr 22
DEF 14A
Definitive proxy
7 Apr 22
DEFA14A
Additional proxy soliciting materials
8 Apr 21
DEF 14A
Definitive proxy
8 Apr 21
DEFA14A
Additional proxy soliciting materials
20 May 20
Other
EFFECT
Notice of effectiveness
12 Aug 21
CORRESP
Correspondence with SEC
5 Aug 21
UPLOAD
Letter from SEC
2 Aug 21
CT ORDER
Confidential treatment order
19 Feb 20
EFFECT
Notice of effectiveness
20 Jul 18
CORRESP
Correspondence with SEC
17 Jul 18
UPLOAD
Letter from SEC
17 Jul 18
EFFECT
Notice of effectiveness
16 Jan 18
CORRESP
Correspondence with SEC
11 Jan 18
CORRESP
Correspondence with SEC
3 Jan 18
Ownership
4
Marianna Mancini
27 Mar 24
4
Brian Lian
27 Mar 24
4
GREG ZANTE
27 Mar 24
4
Brian Lian
4 Mar 24
4
Marianna Mancini
4 Mar 24
4
GREG ZANTE
4 Mar 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Brian Lian
9 Feb 24
144
Notice of proposed sale of securities
9 Feb 24